Table 1.
Demographic characteristics of patients with ROS1+, ALK+, and EGFR+ lung adenocarcinoma
| N | ROS1 |
ALK |
EGFR |
|---|---|---|---|
| 44 | 98 | 168 | |
| Sex (%) | |||
| Female | 30 (68.2) | 49 (50) | 118 (70.2) |
| Male | 14 (31.8) | 49 (50) | 50 (29.8) |
| Age, mean ± SD | 53.06 ± 15.41 (19-90) | 52.77 ± 11.30 (26-80) | 65.84 ± 12.67 (36-89) |
| Smoking (%) | |||
| Nonsmoker | 35 (79.5) | 70 (71.4) | 141 (83.9) |
| Former/current smoker (all tobacco) | 9 (20.5) | 28 (28.6) | 27 (16.1) |
| Staging (%) | |||
| I | 1 (2.3) | 3 (3.0) | 19 (11.3) |
| II | 2 (4.5) | 3 (3.0) | 8 (4.8) |
| III | 8 (18.2) | 28 (28.6) | 17 (10.1) |
| IV | 33 (75) | 64 (65.3) | 124 (73.8) |
| T stage (%) | |||
| T1 | 7 (15.9) | 19 (19.4) | 25 (14.9) |
| T2 | 11 (25) | 24 (24.5) | 47 (28) |
| T3 | 4 (9.1) | 12 (12.2) | 15 (8.9) |
| T4 | 21 (47.7) | 40 (40.8) | 81 (48.2) |
| NA | 1 (2.3) | 3 (3.1) | 0 (0) |
| N stage | |||
| N0 | 3 (6.8) | 15 (15.3) | 48 (28.6) |
| N1 | 6 (13.6) | 8 (8.2) | 18 (10.7) |
| N2 | 14 (31.8) | 37 (37.8) | 49 (29.2) |
| N3 | 20 (45.5) | 35 (35.7) | 53 (31.5) |
| NA | 1 (2.3) | 3 (3.1) | 0 (0) |
| M stage (%) | |||
| M0 | 11 (25) | 34 (34.7) | 68 (40.5) |
| M1 | 33 (75) | 64 (65.3) | 100 (59.5) |
| Median overall survival (months) | 60.9 | 63.1 | 24.5 |
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; SD, standard deviation.